Dr. Jacobson leads the Immune Cell Therapy Program at Dana Farber Cancer Institute. She is leading expert in Hematologic Oncology with special interests in CAR T-cell gene therapy, Lymphoma, Leukemia, Chronic Lymphocytic (CLL), Lymphoma, Hodgkin and Lymphoma, Non-Hodgkin.

Over the past couple of years, Dr. Jacobson and her team tested Yescarta in a clinical trial leading to its FDA approval of this therapy. Her institute, Dana-Farber/Brigham and Women’s Cancer Center, were the only facility in the northeast to be part of the clinical trial, and is one of a few locations certified to offer this new therapy nationwide. The drug, known as Yescarta (axicabtagene ciloleucel), was developed by Kite Pharma and can now be used to treat adults with refractory aggressive B cell non-Hodgkin lymphoma (NHL).

Dr. Jacobson earned her medical degree MD at Columbia University College of Physicians & Surgeons; Residency at New York-Presbyterian Hospital, Columbia University College of Physicians & Surgeons, in Internal Medicine; and completed her Fellowship in Hematology/Oncology at Dana-Farber Cancer Institute. She is Board Certified in: Hematology, Internal Medicine, and Medical Oncology.